Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Equities researchers at Stifel Canada increased their FY2025 earnings estimates for shares of Bradmer Pharmaceuticals in a research report issued on Tuesday, November 12th. Stifel Canada analyst B. Papanastasiou now forecasts that the company will post earnings of $2.28 per share for the year, up from their previous estimate of $1.83.
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported C($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of C($0.52) by C$0.34.
View Our Latest Stock Analysis on GLX
Bradmer Pharmaceuticals Price Performance
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- How to Capture the Benefits of Dividend Increases
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- How to Find Undervalued Stocks
- Top-Performing Non-Leveraged ETFs This Year
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
